Atefeh Mashayekhi

Atefeh Mashayekhi

Auto-generated profile, based on publicly available information

Atefeh Mashayekhi

Optimax Access UK Ltd, Market Access Consultancy, UK; Device Access UK Ltd, Market Access Consultancy, University of Southampton Science Park, Chilworth, Hampshire, UK

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in Journal of Medical Economics
Verified
Journal Article
Open access
MJMehdi Javanbakht
Mehdi Javanbakht
AMAtefeh Mashayekhi
Atefeh Mashayekhi
MTMiranda Trevor
Miranda Trevor
MHMohsen Rezaei Hemami
Mohsen Rezaei Hemami
CDCandice L. Downey
Candice L. Downey
JAJowan Atkinson
Jowan Atkinson
Background: Complications after surgical procedures are common and can lead to a prolonged hospital stay, increased rates of postoperative hospital readmission, and increased mortality. Monitoring vital signs is an effective way to identify patients who are experiencing a deterioration in health. SensiumVitals is wireless system that includes a lightweight, digital patch that monitors vital signs at two minute intervals, and has shown promise in the early identification of patients at high risk of deterioration. Objective: To evaluate the cost-utility of continuous monitoring of vital signs with SensiumVitals in addition to intermittent monitoring compared to the usual care of patients admitted to surgical wards. Methods: A de novo decision analytic model, based on current treatment pathways, was developed to estimate the costs and outcomes. Results from randomised clinical trials and national standard sources were used to inform the model. Costs were estimated from the NHS and PSS perspective. Deterministic and probabilistic sensitivity analyses (PSA) were conducted to explore uncertainty surrounding input parameters. Results: Over a 30-day time horizon, intermittent monitoring in addition to continuous monitoring of vital signs with SensiumVitals was less costly than intermittent vital signs monitoring alone. The total cost per patient was £6,329 versus £5,863 for the comparator and intervention groups respectively and the total effectiveness per patient was 0.057 QALYs in each group. Results from the PSA showed that use of SensiumVitals in addition to intermittent monitoring has 73% probability of being cost-effective at a £20,000 willingness-to-pay threshold and 73% probability of being cost-saving compared to the comparator. Cost savings were driven by reduced costs of hospital readmissions and length of stays in hospital. Conclusions: Use of SensiumVitals as a postoperative intervention for patients on surgical wards is a cost-saving and cost-effective strategy, yielding improvements in recovery with decreased health resource use.

12 December 2012 in Transfusion
Verified
Journal Article
Closed access
PDF file
AKAli Keshtkaran
Ali Keshtkaran
MJMehdi Javanbakht
Mehdi Javanbakht
SSSedigheh Salavati
Sedigheh Salavati
AMAtefeh Mashayekhi
Atefeh Mashayekhi
MKMehran Karimi
Mehran Karimi
BNBijan Nuri
Bijan Nuri

1 January 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
MJMehdi Javanbakht
Mehdi Javanbakht
AMAtefeh Mashayekhi
Atefeh Mashayekhi
MBMichael Branagan-Harris
Michael Branagan-Harris
PHPhilipp Horvath
Philipp Horvath
AKAlfred Königsrainer
Alfred Königsrainer
MYMohsen Yaghoubi
Mohsen Yaghoubi